Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
abandonment, accident, adolescence, Aerial, age, ahead, air, al, answer, API, apnea, approach, arbitrage, Asia, assigned, assignment, assimilating, Austria, awaiting, behavior, bifurcate, BioPharma, Bipartisan, bona, budgetary, build, Canada, captioned, cell, childhood, coincide, Como, compassionate, complement, compliant, complicated, concomitantly, construction, cooperating, copay, CORAR, core, Council, counterfeit, damaged, deadline, defect, defibrotide, Defitelio, delisted, deposit, depository, description, device, diagnosed, differentiated, diligence, discharge, disgorgement, dispersion, disposal, disposing, divalproex, dossier, draft, earthquake, EC, EDS, EEA, elapse, element, EMA, EN, endorsement, entirety, environmental, equitable, erosion, ethical, eventually, explicitly, fide, fiduciary, filer, fire, fixed, flood, fourteen, Framework, Gentium, Germany, GmbH, Greece, Guardia, GvHD, hematology, hematopoietic, heparin, hepatic, HSCT, identical, IMPD, imposition, incorrectly, incremental, indirect, intent, intrinsic, irrespective, ISO, Italian, Italy, Kabi, led, LeukotacTM, living, MAA, Maine, man, Matthew, Mellon, moved, multinational, NADAC, NARP, NASDAQ, nighttime, noncompetitive, noncontrolling, notified, observation, obsolete, obstructive, OIG, omission, overly, parallel, Patheon, PDUFA, pediatric, pegcrisantaspase, people, Perrigo, pharmacokinetic, placebo, plant, preliminary, premised, processor, PTAB, purported, quoted, rarity, reassessment, reauthorization, recurrent, reject, remanded, remeasured, renewal, rescission, safeguard, sBLA, scalable, Scheme, schizoaffective, shift, shifting, short, shortly, Situated, SK, SmPC, solid, South, Southern, Spain, stem, strong, suicidal, sulglicotide, summarized, taxation, telecommunication, tender, tendered, terrorism, Topic, traditional, transplantation, transportation, trend, unfair, unfavorable, UNI, untendered, urokinase, User, variation, vascular, Villa, VOD, voluntarily, wastewater, weekly, wholly, withdrew, workforce, worth, Xavion
Removed:
absent, accelerate, adding, adjustment, alcohol, alprazolam, Alto, aminoglycoside, announcement, antibiotic, appealed, aspect, ATRA, BCA, bioequivalence, calcium, Caphosol, centralized, cited, clarified, collagen, Collatamp, collectively, complied, component, composed, confirmation, constitutional, construing, contraindication, cumulative, cure, Custodiol, declaratory, deducting, denied, derecognition, disaster, dismissal, diversity, equaling, Escherichia, executing, exhibit, expert, fatal, fluvoxamine, Fomepizole, formatting, forward, function, GBP, gentamicin, graft, hearing, host, HTK, implant, impregnated, infrequent, inhibitor, innovative, Kidrolase, learn, left, leveraging, lyophilized, maleate, Markman, measurement, Meda, merged, month, mortality, NAVIGATOR, Niravam, objective, official, originating, Palo, Parcopa, parent, partly, passage, pH, phosphate, platform, post, posted, pretrial, profitable, ProgramTM, recovery, refilled, reflected, rescind, resell, resolve, reuptake, reverse, rinse, segregated, selective, serotonin, shaped, signal, Social, space, Sterling, stricter, sufficiency, supersaturated, supported, surviving, tablet, telephonic, tetrabenazine, threshold, trillion, uncovered, underwriter, uninsured, unobservable, unreported, vacate, vested, viability, vitro, vivo, wholesaler, women, Xenazine
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.3 Offer Letter
- 10.4 JAZZ Pharmaceuticals PLC 2014 Executive Officer Compensation Arrangements
- 10.6 Non-employee Director Compensation Policy
- 31.1 Certification of CEO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 31.2 Certification of CFO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 32.1 Certifications of CEO and CFO Pursuant to 18 U.s.c. Section 1350
- Download Excel data file
- View Excel data file
Related press release
JAZZ similar filings
Filing view
External links
Exhibit 10.4
2014 Executive Officer Compensation Arrangements
Executive Officer | Base Salary Rate(1) | Target Bonus as % of Annual Base Salary Rate(2) |
Bruce C. Cozadd Chairman and Chief Executive Officer | $840,000 | 100 |
Russell J. Cox Executive Vice President and Chief Commercial Officer | $455,000 | 50 |
Suzanne Sawochka Hooper Executive Vice President and General Counsel | $485,000 | 50 |
Fintan Keegan Executive Vice President, Technical Operations | $376,667 | 50 |
Jeffrey K. Tobias, M.D. Executive Vice President, Research and Development and Chief Medical Officer | $430,000 | 50 |
Karen J. Wilson Senior Vice President, Finance and Principal Accounting Officer | $300,000 | 40 |
Matthew P. Young Senior Vice President and Chief Financial Officer | $415,000 | 40 |
(1) | 2014 Base salary rates generally effective by March 1, 2014. Mr. Keegan’s base salary is paid in Euro and is €275,000 for 2014. This conversion to U.S. dollars was calculated based on the average monthly exchange rate for December 2013 as reported by the OANDA Corporation. Mr. Young’s base salary rate is effective beginning on March 9, 2014, the effective date of his appointment as Chief Financial Officer. Prior to March 9, 2014, Mr. Young’s 2014 base salary rate was $360,500. |
(2) | Target bonus percentage for each officer is based on his or her position and/or responsibility level as provided in Jazz Pharmaceuticals plc’s cash bonus plans. |